The information contained on this website is only a summary. You may download a copy of the full Notice by clicking here. Since this website is just a summary, you should review the Notice and Settlement Agreements for additional details. The Settlement Agreements are available by clicking here.

What is the lawsuit about?

Two additional proposed direct purchaser settlements have been reached in a class action lawsuit (“the Lawsuit”), which alleges that Greenstone LLC, Pfizer Inc. and Glenmark Pharmaceutical Inc., USA (collectively “Settling Defendants”) and other generic drug manufacturers violated the federal antitrust laws by conspiring to fix, maintain, and stabilize prices, rig bids, and engage in market and customer allocations of certain generic drugs (the “Named Generic Drugs”), causing direct purchasers of the Named Generic Drugs to pay more than they should have.

The Settling Defendants deny liability as alleged in the Lawsuit. The Court has not decided who is right. The proposed Settlements do not resolve any of the claims of the Settlement Class against the remaining Defendants. The Lawsuit against the remaining non-settled Defendants is ongoing.

Who is included?

You are part of the Settlement Classes if you are a person or entity in the United States and its territories that purchased one or more Named Generic Drugs directly from one or more Current or Former Defendants at any time from May 1, 2009 until December 31, 2019.

Excluded from the Settlement Class are Current and Former Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities

What do the Settlements provide?

The proposed Settlements provide for the following payments: (1) a $33,000,000 payment by Settling Defendants Greenstone LLC and Pfizer Inc. and (2) two payments totaling $37,750,000 by Settling Defendant Glenmark Pharmaceutical Inc., USA. These payments will comprise the total $70,750,000 “Settlement Fund.” The Settlement Fund may be reduced to $62,260,000 or increased to a maximum of $88,405,662.50 under certain circumstances as explained in the Settlement Agreements. In addition, the Direct Purchaser Plaintiff (“DPP”) attorneys who have worked on the Lawsuit for the Settlement Classes will seek Court approval to pay expenses, and service awards for the class representatives (or named plaintiffs) out of the Settlement Fund. DPP attorneys will also request a set-aside for attorneys’ fees of up to one-third of the net Settlement Fund, including interest, after expenses (and service awards) are deducted. The calculations of the dollar amount that each Settlement Class Member will be paid from the Settlement Fund are set forth in the Plan of Allocation, which also is available on GenericDrugsDirectPurchaserSettlement.com. In conjunction with the distribution of the Settlement Fund, DPP attorneys intend to also distribute to members of these Settlement Classes $1,846,000 (plus any additional accrued interest) from a bankruptcy involving Defendant Mallinckrodt Inc. and its affiliates (“Mallinckrodt monies”). DPP attorneys do not intend to seek expenses, service awards, or a set-aside for a future request for attorneys’ fees from the Mallinckrodt monies.

These rights and options – and the deadlines to exercise them – are explained in the Notice .